A new study explores how healthcare providers can effectively implement Apretude for HIV pre-exposure prophylaxis (PrEP) ...

Whitman-Walker Health highlights the importance of PrEP in HIV prevention and encourages collective action to increase access ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...

Increasing the use of Apretude among Black women requires not only expanding awareness of the long-acting PrEP regimen in ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections.

Pharmaceutical company Gilead Sciences announced Wednesday the Food and Drug Administration (FDA) has approved its six-month, twice-yearly HIV PrEP injection, which was found in trials to be more ...

Announced at the International AIDS Society (IAS) 2025 conference taking place from 13-17 July in Kigali, Rwanda, MSD has launched two Phase III trials, EXPrESSIVE-10 and EXPrESSIVE-11, which will ...

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo (lenacapavir), a new era of HIV prevention has dawned. The approval ...

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug Administration to be used to prevent HIV.